CompletedPhase 1NCT04650555
BIO 300 Oral Powder Safety and Pharmacokinetics
Studying Acute radiation syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Humanetics Corporation
- Principal Investigator
- Michael D Kaytor, Ph.D.Humanetics Corporation
- Intervention
- BIO 300 Oral Powder(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Nucleus Network, Ltd (Formally Prism Research, LLC), Saint Paul, Minnesota, United States
Collaborators
United States Department of Defense · Joint Warfighter Medical Research Program
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04650555 on ClinicalTrials.govOther trials for Acute radiation syndrome
Additional recruiting or active studies for the same condition.